Advanced Cell Diagnostics Growth, Revenue, Number of Employees and Funding
Navigation
Overview
Estimated Revenue & Financials
- Advanced Cell Diagnostics's estimated revenue is currently $25.7M per year.
- Advanced Cell Diagnostics received $22.0M in venture funding in June 2015.
- Advanced Cell Diagnostics's estimated revenue per employee is $144551
Employee Data
- Advanced Cell Diagnostics has 178 Employees.
- Advanced Cell Diagnostics grew their employee count by 8% last year.
- Advanced Cell Diagnostics currently has N/A job openings.
Executive Contacts
| Name | Title |
|---|---|
| Xiao-Jun Ma | Chief Scientific Officer |
| Christopher Bunker | Vice President, Business Development |
| Deborah Wright | VP RA/QA |
| Jessie Wang | Chief Financial Officer |
| Ruby Hsu | Director, Market Development |
| Tony Lam | VP Regulatory Affairs and Quality Assurance |
| Dan Zhang | Senior Director Of Operations |
| Nathalie Koch | Associate Director, Marketing at Advanced Cell Diagnostics |
| Tom O'Lenic | Chief Commercial Officer |
| Henry Lamparski | Senior Director (IVD) Product Development |
What Is Advanced Cell Diagnostics?
ACD - a Bio-Techne brand, (www.acdbio.com) shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research and diagnostic tests for personalized medicine. Based in Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD's products and pharma assay services are based on its proprietary RNAscope® technology ( 1200+ publications in 6 years), the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope and BaseScope(tm) in addition to a Pharma Assay Services business. The catalog includes >10,000 target probes and assay kits for single, duplex and multiplex RNA analysis. www.acdbio.com
keywords:N/A178
Number of Employees
$25.7M
Revenue (est)
N/A
Current Jobs
8%
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
N/A
Type
Similar Companies
| Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
| $6.2M | 43 | 10% | N/A | |
| $10.7M | 74 | 45% | N/A | |
| $42M | 290 | 4% | N/A | |
| $26.4M | 182 | 3% | N/A | |
| $5.9M | 41 | 37% | N/A | |
| $25.7M | 178 | 8% | N/A | |
| $5.7M | 40 | 11% | N/A | |
| $4.2M | 33 | -15% | N/A | |
| $6M | 42 | 5% | N/A | |
| $7.1M | 49 | -2% | N/A |
Advanced Cell Diagnostics News
Crucial players are analyzed Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, ...
... Analysis Of the global RNA In Situ Hybridization Market includes Abbott, Biogenex, Biosb, Roche, Sigma-Aldrich, Advanced Cell Diagnostics, ...
A comprehensive research study on Circulating Tumor Cell Diagnostics market added by Market Study Report provides insights into the market ...
Advanced Cell Diagnostics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-09-03 | $5.4M | Undisclosed | Morningside Ventures | Article |
| 2012-11-02 | $12.0M | Undisclosed | New Leaf Venture Partners, Morningside Ventures | Article |
| 2015-06-19 | $22.0M | C | Summit Partners | Article |
Advanced Cell Diagnostics Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2013-01-28 | Evangeline Gonzalez | Chief Commercial Officer | Article |
| 2014-12-03 | Tom Olenic | Chief Commercial Officer | Article |
| 2015-12-17 | Robert J. Monroe | Chief Medical Officer | Article |